Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis

Josephine F. Trott, Vicki J. Hwang, Tatsuto Ishimaru, Kenneth J. Chmiel, Julie X. Zhou, Kyuhwan Shim, Benjamin J. Stewart, Moe R. Mahjoub, Kuang-Yu Jen, Dinesh K. Barupal, Xiaogang Li, Robert H Weiss

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter is currently being studied as a metabolic disease. In clear cell renal cell carcinoma (RCC), which is now considered a metabolic disease, we and others have shown derangements in the enzyme arginosuccinate synthase 1 (ASS1), resulting in RCC cells becoming auxotrophic for arginine and leading to a new therapeutic paradigm involving reducing extracellular arginine. Based on our earlier finding that glutamine pathways are reprogrammed in ARPKD, and given the connection between arginine and glutamine synthetic pathways via citrulline, we investigated the possibility of arginine reprogramming in ADPKD. We now show that, in a remarkable parallel to RCC, ASS1 expression is reduced in murine and human ADPKD, and arginine depletion results in a dose-dependent compensatory increase in ASS1 levels as well as decreased cystogenesis in vitro and ex vivo with minimal toxicity to normal cells. Nontargeted metabolomics analysis of mouse kidney cell lines grown in arginine-deficient versus arginine-replete media suggests arginine-dependent alterations in the glutamine and proline pathways. Thus, depletion of this conditionally essential amino acid by dietary or pharmacological means, such as with arginine-degrading enzymes, may be a novel treatment for this disease.

Original languageEnglish (US)
Pages (from-to)F1855-F1868
JournalAmerican journal of physiology. Renal physiology
Volume315
Issue number6
DOIs
StatePublished - Dec 1 2018

    Fingerprint

Keywords

  • arginine
  • cystogenesis
  • metabolic reprogramming

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Trott, J. F., Hwang, V. J., Ishimaru, T., Chmiel, K. J., Zhou, J. X., Shim, K., Stewart, B. J., Mahjoub, M. R., Jen, K-Y., Barupal, D. K., Li, X., & Weiss, R. H. (2018). Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. American journal of physiology. Renal physiology, 315(6), F1855-F1868. https://doi.org/10.1152/ajprenal.00025.2018